Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
FDA approves spray for plaque psoriasis
The Food and Drug Administration has approved a new drug application for Taro Pharmaceutical Industry’s Topicort (desoximetasone 0.25 percent) topical spray for the treatment of plaque psoriasis.
The Food and Drug Administration has approved a new drug application for Taro Pharmaceutical Industry’s Topicort (desoximetasone 0.25 percent) topical spray for the treatment of plaque psoriasis.
The corticosteroid is indicated for the treatment of plaque psoriasis in patients ages 18 and older. Annual sales for corticosteroid sprays in the United States total about $100 million, according to a news release.
Related Videos
Related Content
